Two patients were receiving a maintenance treatment with rituximab (Patient 4) or a fludarabine-based chemotherapy associated with rituximab (Patient 5) for a low grade lymphoma that was in complete remission at time of CD8+ T-cell expansion diagnosis. This evidence concerns the gene CD8A and lymphoma.